After selling the PerkinElmer name and several ancillary business units, Prahlad Singh (CEO) and his team at the newly christened Revvity faced a challenge on how best to capitalize on the opportunities ahead for the business and emerge as winners within the Life Sciences and Diagnostics industries. Would the focus on Life Sciences and Diagnostics allow Singh to capture the value in the market that eluded him when PerkinElmer was saddled with other non-core businesses, or would challenges persist by trading at lower multiples than their peers? Singh and the company had a clean slate, and needed to craft a corporate strategy that focused on core strengths and showcased the unpolished gems that Revvity had acquired and polished into a global stable of respected brands.